Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...